130,447 Shares in Merit Medical Systems, Inc. $MMSI Bought by Ranger Investment Management L.P.

Posted by Brenda Bartman on Aug 24th, 2026

Ranger Investment Management L.P. purchased a new stake in Merit Medical Systems, Inc. (NASDAQ:MMSI – Free Report) in the 2nd quarter, according to its most recent filing with the SEC. The institutional investor purchased 130,447 shares of the medical instruments supplier’s stock, valued at approximately $9,045,000. Ranger Investment Management L.P. owned approximately 0.22% of Merit Medical Systems at the end of the most recent quarter.

Several other hedge funds also recently added to or reduced their stakes in the stock. Kilter Group LLC purchased a new stake in shares of Merit Medical Systems in the second quarter worth about $25,000. Los Angeles Capital Management LLC purchased a new stake in shares of Merit Medical Systems during the 4th quarter valued at about $25,000. Torren Management LLC purchased a new stake in shares of Merit Medical Systems during the 4th quarter valued at about $38,000. Covestor Ltd lifted its position in Merit Medical Systems by 252.6% during the 4th quarter. Covestor Ltd now owns 469 shares of the medical instruments supplier’s stock worth $41,000 after acquiring an additional 336 shares in the last quarter. Finally, Danske Bank A S acquired a new position in Merit Medical Systems during the 3rd quarter worth approximately $42,000. 99.66% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on MMSI. Weiss Ratings raised shares of Merit Medical Systems from a “hold (c-)” rating to a “hold (c)” rating in a research report on Tuesday, August 18th. BTIG Research restated a “buy” rating and issued a $105.00 target price on shares of Merit Medical Systems in a research note on Tuesday, August 11th. Wells Fargo & Company raised their price target on shares of Merit Medical Systems from $74.00 to $83.00 and gave the company an “equal weight” rating in a report on Friday, July 31st. Raymond James Financial reaffirmed an “outperform” rating and set a $100.00 price target on shares of Merit Medical Systems in a research note on Friday, July 31st. Finally, Robert W. Baird set a $98.00 price objective on shares of Merit Medical Systems in a research report on Friday, July 31st. Eight investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $100.00.

View Our Latest Stock Report on MMSI

Merit Medical Systems Price Performance

Shares of NASDAQ:MMSI opened at $90.78 on Monday. The company has a market cap of $5.42 billion, a PE ratio of 37.51, a P/E/G ratio of 2.28 and a beta of 0.48. Merit Medical Systems, Inc. has a fifty-two week low of $59.74 and a fifty-two week high of $94.75. The firm has a 50-day simple moving average of $77.41 and a 200 day simple moving average of $72.51. The company has a quick ratio of 2.79, a current ratio of 4.20 and a debt-to-equity ratio of 0.44.

Merit Medical Systems (NASDAQ:MMSI – Get Free Report) last issued its earnings results on Thursday, July 30th. The medical instruments supplier reported $1.19 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.96 by $0.23. Merit Medical Systems had a net margin of 9.22% and a return on equity of 13.75%. The firm had revenue of $418.84 million for the quarter, compared to analysts’ expectations of $405.25 million. During the same quarter last year, the company posted $1.01 earnings per share. Merit Medical Systems’s revenue was up 9.5% on a year-over-year basis. Merit Medical Systems has set its FY 2026 guidance at 4.250-4.350 EPS. On average, sell-side analysts anticipate that Merit Medical Systems, Inc. will post 3.81 EPS for the current year.

About Merit Medical Systems

(Free Report)

Merit Medical Systems, Inc is a global manufacturer and marketer of a broad range of medical devices used in diagnostic and interventional procedures. The company’s product portfolio encompasses vascular access, drainage, embolotherapy, and interventional oncology devices, as well as radiofrequency ablation systems and hemostasis solutions. These products serve physicians and hospitals in critical care settings and support minimally invasive treatment options across multiple specialties, including cardiology, radiology, oncology, neurology and endoscopy.

Founded in 1987 by Fred Lampropoulos, Merit Medical Systems has grown through both organic development and targeted acquisitions to expand its technology offerings and geographic reach.